» Articles » PMID: 36418753

Characterization of Sebaceous and Non-sebaceous Cutaneous Manifestations in Patients with Lynch Syndrome: a Systematic Review

Overview
Journal Fam Cancer
Publisher Springer
Specialty Oncology
Date 2022 Nov 23
PMID 36418753
Authors
Affiliations
Soon will be listed here.
Abstract

A subset of patients with Lynch Syndrome demonstrates cutaneous manifestations of the disorder. Characterization of these Lynch-related skin lesions could help in early recognition of patients with Lynch Syndrome. A broad search of the literature on OVID Medline and Embase was carried out to capture papers reporting cutaneous manifestations in Lynch Syndrome patients. The results were uploaded into Mendeley reference management software. The PRISMA workflow was used in the literature selection process. In this systematic review, data were collected from 961 cases from 413 studies, including 380 molecularly confirmed Lynch Syndrome cases. The main skin lesions were: Sebaceous adenomas (43%), sebaceous carcinomas (27%), keratoacanthomas (16%), sebaceomas (13%), squamous cell carcinomas (23%), and basal cell carcinomas (10%). MSH2 variants were the most common underlying genotype (72%). Assessment of mismatch repair by immunohistochemistry, microsatellite instability analysis, or both were performed on 328 skin lesions from 220 (58%) molecularly confirmed cases. In those skin lesions, 95% of Immunohistochemistry and 90% of the microsatellite instability test results were concordant with the underlying genotype. Sebaceous skin lesions are well-recognised phenotypic features of Lynch Syndrome. Our results show that squamous and basal cell carcinomas are relatively common in patients with Lynch syndrome; however, available evidence cannot confirm that Lynch syndrome is causal. Immunohistochemistry and/or microsatellite instability testing of skin tumours in patients with a family history of Lynch Syndrome-associated cancers may be a useful approach in identifying patients requiring referral to Clinical Genetics and/or consideration of germline genetic testing for Lynch Syndrome.

Citing Articles

Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm.

Dobre A, Nedelcu R, Turcu G, Brinzea A, Struna I, Tudorache G Am J Clin Dermatol. 2024; 26(1):45-59.

PMID: 39572470 PMC: 11742465. DOI: 10.1007/s40257-024-00900-0.


Incidental melanoma and thyroid cancer lead to diagnosis of Lynch syndrome and endometrial cancer: A case report.

Kuo M, Smith E, Plotzke J, Chan M, Else T, Cha K JAAD Case Rep. 2024; 51:66-68.

PMID: 39188332 PMC: 11347038. DOI: 10.1016/j.jdcr.2024.06.023.


Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.

Weber C, Kronke N, Volk V, Auber B, Forster A, Trost D Acta Neuropathol Commun. 2023; 11(1):184.

PMID: 37990341 PMC: 10664377. DOI: 10.1186/s40478-023-01689-5.


Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.

Cohen P, Kurzrock R Cureus. 2023; 15(1):e33975.

PMID: 36824550 PMC: 9941027. DOI: 10.7759/cureus.33975.

References
1.
Vermaut C, Leclerc J, Vasseur F, Wacrenier A, Lovecchio T, Boidin D . MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France. Genes Chromosomes Cancer. 2019; 59(2):111-118. DOI: 10.1002/gcc.22804. View

2.
Lobo J, Pinto C, Freitas M, Pinheiro M, Vizcaino R, Oliva E . Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?. Virchows Arch. 2016; 470(3):347-352. DOI: 10.1007/s00428-016-2052-4. View

3.
John A, Schwartz R . Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. J Am Acad Dermatol. 2016; 74(3):558-66. DOI: 10.1016/j.jaad.2015.09.074. View

4.
Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F . Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009; 75(2):141-9. DOI: 10.1111/j.1399-0004.2008.01125.x. View

5.
Monahan K, Alsina D, Bach S, Buchanan J, Burn J, Clark S . Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ. 2017; 356:j1388. DOI: 10.1136/bmj.j1388. View